Review Article: A Reevaluation of the Clinical Significance of Histological Subtyping of Non—Small-Cell Lung Carcinoma: Diagnostic Algorithms in the Era of Personalized Treatments
Restricted accessReview articleFirst published online June, 2009
Review Article: A Reevaluation of the Clinical Significance of Histological Subtyping of Non—Small-Cell Lung Carcinoma: Diagnostic Algorithms in the Era of Personalized Treatments
The classification of lung cancer has always been primarily based on the morphologic assessment of routinely stained histological sections, but this approach may be difficult or even unfeasible in cytological preparations or small biopsies. Moreover, the simplistic dichotomization between small-cell carcinoma and non-small cell carcinoma (NSCLC) should be overcome, as new drugs have been discovered that are effective in specific subtypes of lung cancer. A more accurate characterization of NSCLC, however, may be hard in carcinomas lacking clear-cut signs of differentiation. The incorporation into the diagnostic algorithm of poorly differentiated carcinomas of an immunohistochemical panel including markers of squamous (high-molecular-weight cytokeratins, p63) and glandular (TTF-1, cytokeratin 7) cell differentiation seems the most promising approach. The evaluation of lung cancer for gene mutations, gene amplification, tumor-related angiogenesis, expression levels of DNA repair genes and genomic or proteomic profiles represents an exciting challenge for the pathologist in the near future.
World Health Organization.Histological typing of lung tumors. International Histological Classification of Tumours. No. 1. Geneva, Switzerland: World Health Organization; 1967.
2.
World Health Organization. Histological typing of lung tumors. Vol. 1. 2nd ed. International Histological Classification of Tumours. No. 1Geneva: World Health Organization; 1981.
3.
World Health Organization.The World Health Organization histological typing of lung tumours. 2nd ed. Am J Clin Pathol. 1982 ;77:123-136.
4.
Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, eds. Tumours of the lung, pleura, thymus and heart. Pathology and Genetics. WHO Classification of Tumours. Lyon, France: IARC Press; 2004.
5.
Colby TV, Koss MN, Travis WDAtlas of Tumor Pathology. 3rd series. Tumors of the lower respiratory tract . Washington, DC: Armed Forces Institute of Pathology; 1995.
6.
Edwards SL, Roberts C., McKean ME, Cockburn JS, Jeffrey RR, Kerr KMPreoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the nonsmall cell category. J Clin Pathol. 2000;53:537-540.
7.
Colby TV, Leslie KO, Yousem SASection VIThorax and serous membranes. Chap. 18: Lungs. In: Histology for Pathologists. Mills SE, ed. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007.
8.
Albain KS, Crowley JJ, LeBlanc M., Livingston RBSurvival determinants in extensive-stage non-small cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol. 1991 ;9:1618-1626.
9.
Schiller JH, Harrington D., Belani C., et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med. 2002;346:92-98.
10.
Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: update 2003. J Clin Oncol. 2004;22:330-353.
11.
Scagliotti GV, Parikh P., von Pawel J., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced stage non-small-cell lung cancer. J Clin Oncol . 2008;26:3543-3551.
12.
Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J Clin Oncol. 2003;21:2237-2246.
13.
Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the EGFR tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial . JAMA. 2003;290:2149-2158.
14.
Giaccone G., Herbst RS, Manegold C., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small cell lung cancer: a phase III trial-INTACT. J Clin Oncol. 2004;22:777-784.
15.
Herbst RS, Prager D., Hermann R., et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small cell lung cancer. J Clin Oncol. 2005;23:5892-5899.
16.
Janne PAOngoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations. Semin Oncol. 2005;32(suppl 10):S9-S15.
17.
Shepherd FA, Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med. 2006;353:123-132.
18.
Wheatley-Price P., Shepherd FAEpidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes. Curr Opin Oncol. 2008;20:162-175.
19.
Herbst RS, Johnson DH, Mininberg E., et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor Erlotinib for patients with recurrent non-small cell lung cancer. J ClinOncol. 2005;23:2544-2555
20.
Johnson DH, Fehrencbacher L., Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer. J Clin Oncol. 2004;22:2184-2191.
21.
Sandler A., Gray R., Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542-2550.
22.
Hirsch FR, Spreafico A., Novello S., et al. The prognostic and predictive role of histology in advanced non-small cell lung cancer. A literature review. J Thorac Oncol. 2008;3:1468-1481.
23.
Corrin B.Pathology of the Lungs. London, UK: Churchill Livingstone;2000.
24.
Morishita Y. , Fukasawa M., Takeuchi M., Inadome Y., Matsuno Y., Noguchi M.Small-sized adenocarcinoma of the lung. Cytologic characteristics and clinical behavior. Cancer. 2001;93;124-131.
25.
Shimosato Y.Pulmonary neoplasms . In: Sternberg SS, ed. Diagnostic Surgical Pathology. New York, NY: Raven Press;1994:1045-1093.
26.
Motoi N., Szoke J., Riely GJ, et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol. 2008;32:810-827.
27.
Marchetti A. , Martella C., Felicioni L., et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol. 2005; 23:857-865.
28.
Garfield DH , Cadranel J., West HLBronchioloalveolar carcinoma: the case for two diseases. Clin Lung Cancer. 2008;9:24-29.
29.
Nicholson SA , Beasley MB, Brambilla E., et al. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol. 2002;26:1184-1197.
30.
Rossi G., Cavazza A., Marchioni A., et al. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol. 2005;23:8774-8785.
31.
Veronesi G. , Morandi U., Alloisio M., et al. Large cell neuroendocrine carcinoma of the lung: a retrospective analysis of 144 surgical cases. Lung Cancer. 2006;53: 111-115.
32.
Pelosi G., Rodriguez J., Viale G., Rosai J.Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients. Am J Surg Pathol. 2005;29:179-187.
33.
Rossi G., Marchioni A., Sartori G., et al. Histotype in nonsmall cell lung cancer therapy and staging: the emerging role of an old and underrated factor. Curr Respir Med Rev. 2007;3:69-77.
34.
Beasley MBImmunohistochemistry of pulmonary and pleural neoplasia. Arch Pathol Lab Med. 2008;132: 1062-1072.
35.
Jagirdar J.Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma of the lung. Arch Pathol Lab Med. 2008;132:384-396.
36.
Chu PG, Weiss LMKeratin expression in human tissues and neoplasms. Histopathology . 2002;40:403-439.
37.
Rossi G., Marchioni A., Milani M., et al. TTF-1, cytokeratin 7, 34beta E12, and CD56/NCAM immunostaining in the subclassification of large cell carcinomas of the lung. Am J Clin Pathol. 2004;122:884-893.
38.
Sturm N., Rossi G., Lantuejoul S., et al. Expression of thyroid transcription factor-1 in the spectrum of neuroendocrine cell proliferations with special interest in carcinoids . Hum Pathol. 2002;33:175-182.
39.
Kaufmann O. , Dietel M.Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology. 2000;36:8-16.
40.
Ordonez NGThyroid transcription factor-1 is a marker of lung and thyroid carcinomas . Adv Anat Pathol. 2000;7:123-127.
41.
Nakamura N. , Miyagi E., Murata S., Kawaoi A., Katoh R.Expression of thyroid transcription factor-1 in normal and neoplastic lung tissues. Mod Pathol. 2002;15:1058-1067.
42.
Pelosi G., Fraggetta F., Pasini F., et al. Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell carcinomas of the lung. Am J Surg Pathol . 2001;25: 363-372.
43.
Lyda MH, Weiss LMImmunoreactivity for epithelial and neuroendocrine antibodies are useful in the differential diagnosis of lung carcinomas. Hum Pathol . 2000;31:980-987.
44.
Viberti L., Bongiovanni M., Croce S., Bussolati G.34βE12 cytokeratin immunodetection in the differential diagnosis of small cell tumors of the lung. Int J Surg Pathol. 2000;8:317-322.
45.
Sturm N., Lantuejoul S., Laverriere MH, et al. Thyroid transcription factor 1 and cytokeratins 1, 5, 10, 14 (34βE12) expression in basaloid and large-cell neuroendocrine carcinomas of the lung. Hum Pathol. 2001;32: 918-925.
46.
Sturm N., Rossi G., Lantuejoul S., et al. 34betaE12 expression along the whole spectrum of neuroendocrine proliferations of the lung, from neuroendocrine cell hyperplasia to small cell carcinoma. Histopathology. 2003;42:156-166.
47.
Kaufmann O. , Fietze E., Mengs J., Dietel M.Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol. 2001;116: 823-830.
48.
Pelosi G., Pasini F., Olsen Stenholm C., et al. p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas? J Pathol. 2002;198:100-109.
49.
Wang BY, Gil J., Burstein DE, et al. p63 in pulmonary epithelium, pulmonary squamous neoplasms and other pulmonary tumors. Hum Pathol. 2002;33:921-926.
50.
Wu M., Wang B., Gil J., et al. p63 and TTF-1 immunostaining. A useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung. Am J Clin Pathol. 2003;119:696-702.
51.
Johansson L.Histopathologic classification of lung cancer: relevance of cytokeratin and TTF-1 immunophenotyping. Ann Diagn Pathol. 2004;8:259-267.
52.
Shtilbans V. , Szporn AH, Wu M., Burstein DEp63 immunostaining in destained bronchoscopic cytological specimens. Diagn Cytopathol. 2005 ;32:198-203.
53.
Wu M., Szporn AH, Zhang D., et al. Cytology applications of p63 and TTF-1 immunostaining in differential diagnosis of lung cancers. Diagn Cytopathol. 2005;33: 223-227.
54.
Wu M., Orta L., Gil J., et al. Immunohistochemical detection of XIAP and p63 in adenomatous hyperplasia, atypical adenomatous hyperplasia, bronchioloalveolar carcinoma and well differentiated adenocarcinom. Mod Pathol. 2008;21:553-558.
55.
Kargi A., Gurel D., Tuna B.The diagnostic value of TTF-1, CK5/6, and p63 immunostaining in classification of lung carcinomas. Appl Immunohistochem Mol Morphol. 2007;15:415-420.
56.
Camilo R., Capelozzi VL, Coelho Siqueira SA, Del Carlo Bernardi F.Expression of p63, keratin 5/6, keratin 7 and surfactant-A in non-small cell lung carcinomas. Hum Pathol. 2007;37:542-546.
57.
Downey P., Cummins R., Moran M., Gulmann C.If it's not CK5/6 positive, TTF-1 negative it's not a squamous cell carcinoma of lung. APMIS. 2008;116:526-529.
58.
Zhang H., Cagle PT, Allen TC, et al. Distinction of pulmonary small cell carcinoma from poorly differentiated squamous cell carcinoma: an immunohistochemical approach. Mod Pathol. 2005;18:111-118.
59.
Kalhor N., Zander DS, Liu J.TTF-1 and p63 for distinguishing pulmonary small-cell carcinoma from poorly differentiated squamous cell carcinoma in previously pap-stained cytologic material. Mod Pathol. 2006;19: 1117-1123.
60.
Pelosi G., Pasini F., Sonzogni A., et al. Prognostic implications of neuroendocrine differentiation and hormone production in stage I non-small cell lung cancer. Cancer. 2003;97:2487-2497.
61.
Cheuk W., Chan JKSubcellular localization of immunohistochemical signals: knowledge of the ultrastructural or biologic features of the antigens helps predict the signal localization and proper interpretation of immunostains. Int J Surg Pathol. 2004;12:185-206.
62.
Dejmek A., Naucler P., Smedjeback A., et al. Napsin-A (TA02) is a useful alternative to thyroid transcription factor-1 (TTF-1) for the identification of pulmonary adenocarcinoma cells in pleural effusions. Diagn Cytopathol. 2007 ;35:493-497.
63.
Monica V., Ceppi P., Righi L., et al. Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung [published online ahead of print March 13, 2009]. Mod Pathol. doi:10.1038/ modpathol.2009.30.
64.
Savic S., Tapia C., Grilli B., et al. Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers. Br J Cancer. 2008;15;98:154-160.
65.
Soh J., Toyooka S., Aoe K., et al. Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer. Int J Cancer. 2006;119:2353-2358.
66.
Bunn PA Jr, Franklin W.Epidermal growth factor receptor expression, signal pathway, and inhibitors in nonsmall cell lung cancer. Semin Oncol. 2002;29(5 suppl 14):38-44.
67.
Herbst RS, Bunn PA Jr.Targeting the epidermal growth factor receptor in non-small cell lung cancer . Clin Cancer Res. 2003;9:5813-5824.
68.
Herbst RS, Fidler IJAngiogenesis and lung cancer: potential for therapy. Clin Cancer Res. 2000;6:4604-4606.
69.
Minna JD, Gazdar AF, Sprang SR, Herz J.Cancer. A bull's eye for targeted lung cancer therapy. Science . 2004;304:1458-1461.
70.
Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-1500.
71.
Lynch TJ, Bell DW, Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-2139.
72.
Pao W., Miller V., Zakowski M., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004 ;101:13306-13311.
73.
Cappuzzo F., Hirsch FR, Rossi E., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst . 2005;97:643-655.
74.
Kosaka T., Yatabe Y., Endoh H., et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 2004;64:8919-8923.
75.
Hirsch FR, Varella-Garcia M., Bunn PA Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003;21:3798-3807.
76.
Takano T., Ohe Y., Sakamoto H., et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005;23:6829-6837.
77.
HumbletY.Cetuximab: an IgG (1) monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours. Expert Opin Pharmacother . 2004;5: 1621-1633.
78.
Heymach JV, Nilsson M., Blumenschein G., et al. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin Cancer Res . 2006;12:4441s-4445s.
79.
Helfrich BA , Raben D., Varella-Garcia M., et al. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin Cancer Res. 2006;12:7117-7125.
80.
Lord RV, Brabender J., Gandara D., et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res. 2002;8:2286-2291.
81.
Olaussen KA , Dunant A., Fouret P., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355: 983-991.
82.
Rosell R., Crino L., Danenberg K., et al. Targeted therapy in combination with gemcitabine in non-small cell lung cancer. Semin Oncol. 2003;30(suppl 10):19-25.
83.
Bos JLras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682-4689.
84.
Pao W., Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005;2:e17.
85.
Wu JY, Wu SG, Yang CH, et al. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res. 2008;14:4877-4882.
86.
Folkman J.Tumor angiogenesis. Adv Cancer Res. 1985;43:175-203.
87.
Sandler A.Bevacizumab in non small cell lung cancer. Clin Cancer Res . 2007;13:4613-4616.
88.
Boukovinas I., Papadaki C., Mendez P., et al. Tumor BRCA1, RRM1, and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small cell lung cancer patients. PLos ONE. 2008;3:e3695.
89.
Rosell R., Skrzypski M., Jassem E., et al. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS ONE. 2008;2:e1129.
90.
Ceppi P., Volante M., Novello S., et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol. 2006;17: 1818-1825.
91.
Bepler G., Sommers KE, Cantor A., et al. Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable nonsmall cell lung cancer. J Thorac Oncol. 2008;3: 1112-1118.
92.
Ceppi P., Volante M., Saviozzi S., et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer. 2006;107: 1589-1596.
Singhal S., Miller D., Ramalingam S., Sun SYGene expression profiling of non-small cell lung cancer. Lung Cancer. 2008;60:313-324.
95.
Borczuk AC, Gorenstein L., Walter KL, et al. Non-small-cell lung cancer molecular signatures recapitulate lung developmental pathways. Am J Pathol. 2003;163: 1949-1960.
96.
Lu Y., Lemon W., Liu PY, et al. A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med.2006;3:e467.
97.
Bianchi F., Nuciforo P., Vecchi M., et al. Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. J Clin Invest. 2007;117:3436-3444.
98.
Marko-Varga G., Ogiwara A., Nishimura T., et al. Personalized medicine and proteomics: lessons from non-small cell lung cancer. J Proteome Res. 2007;6: 2925-2935.
